Concepedia

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial

Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura,

Lung Cancer · 2024 · 18 citations · 23 references

DOIFull text

Open access

Concepts

References

23

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

Junji Matsui, Yuji Yamamoto, Yasuhiro Funahashi et al. · International Journal of Cancer · 2007 · 547 citations

, , +17

Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

Junji Matsui, Yasuhiro Funahashi, Toshimitsu Uenaka et al. · Clinical Cancer Research · 2008 · 528 citations · Full text

, , +17

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima et al. · Vascular Cell · 2014 · 500 citations · Full text

, , +16

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Osamu Tohyama, Junji Matsui, Kotaro Kodama et al. · Journal of Thyroid Research · 2014 · 480 citations · Full text

, , +17

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

Giuseppe Giaccone, Chul Kim, Jillian Thompson et al. · The Lancet Oncology · 2018 · 400 citations · Full text

, , +10